Disc Medicine
IRON · Nasdaq · United States
Share price · IRON
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IRON's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Oct 2026+38.9%
- 11 Sep 2026-5.5%
- 30 Jul 2026+7.5%
- 1 Jul 2026+2.5%
- 26 Jun 2026+6.6%
Nothing announced by IRON that day or the session before.
- 1 Jun 2026+3.4%
Nothing announced by IRON that day or the session before.
- 17 Feb 2026+17.2%
- 13 Feb 2026-21.9%
- 9 Feb 2026-7.8%
Nothing announced by IRON that day or the session before.
- 27 Jan 2026+5.9%
Nothing announced by IRON that day or the session before.
Share of unusual movement by asset
For each asset, the share of IRON's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Glycine transporter type 1 (GlyT1)Small molecule | Porphyria Erythropoietic Protoporphyria | |
| Phase 2 | TMPRSS6 (matriptase-2)Monoclonal antibody | Sickle Cell DiseasePolycythemia Vera | |
| Phase 1/2 | Hemojuvelin (HJV)Monoclonal antibody | Chronic Kidney DiseaseMyelofibrosis Anemia of Myelofibrosis |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
May 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $44M | $90M+ $593M short-term inv. | $60M-$40M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $47M | $99M+ $619M short-term inv. | $60M-$44M operating cash flow | report ↗ |
| 2026-Q1 | — | $46M | $89M+ $641M short-term inv. | $64M-$62M operating cash flow | report ↗ |
| 2025-Q3 | — | $50M | $141M+ $475M short-term inv. | $62M-$48M operating cash flow | report ↗ |
| 2025-Q2 | — | $46M | $128M+ $523M short-term inv. | $55M-$48M operating cash flow | report ↗ |
| 2025-Q1 | — | $28M | $123M+ $572M short-term inv. | $34M-$41M operating cash flow | report ↗ |
| 2024-Q3 | — | $25M | $193M+ $295M short-term inv. | $27M-$17M operating cash flow | report ↗ |
| 2024-Q2 | — | $23M | $281M+ $220M short-term inv. | $26M-$15M operating cash flow | report ↗ |
| 2024-Q1 | — | $24M | $343M | $27M-$34M operating cash flow | report ↗ |
| 2023-Q3 | — | $14M | $371M | $14M-$7.5M operating cash flow | report ↗ |
| 2023-Q2 | — | $12M | $378M | $16M-$13M operating cash flow | report ↗ |
| 2023-Q1 | — | $20M | $237M | $23M-$35M operating cash flow | report ↗ |
| 2022-Q3 | — | $0.4M | $102M | $3.3M-$4.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.6M | $109M | $7.1M-$9.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $9.8M | $119M | $15M-$16M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | $150M | $19M-$16M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $171M | $91M+ $700M short-term inv. | $53M-$180M operating cash flow | report ↗ |
Disc Medicine reported no revenue disclosure for FY2025. R&D expenses were $170.64M, up 76.5% YoY from $96.67M, and the company ended the year with cash, cash equivalents, and marketable securities of $791.2M, compared to $489.9M at the end of 2024. Full-year net loss was $212.18M.
Management expects existing cash to fund operations into 2029. In the pipeline, the company received a CRL from the FDA for bitopertin in EPP in February 2026; Phase 3 APOLLO enrollment is expected to complete in March 2026 with topline data expected in Q4 2026. Initial Phase 2 data for DISC-0974 in anemia of myelofibrosis were presented at ASH, a Phase 2 IBD study was initiated in Q1 2026, and DISC-3405 studies in polycythemia vera and sickle cell disease are ongoing with data expected in 2H 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $97M | $193M+ $297M short-term inv. | $27M-$94M operating cash flow | report ↗ |
| 2023-FY | — | $69M | $361M+ $0 short-term inv. | $19M-$73M operating cash flow | report ↗ |
| 2022-FY | — | $33M | $195M | $12M-$42M operating cash flow | report ↗ |
| 2021-FY | — | $49M | $137M | $18M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 97 sales ($48.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Savage William Jacob · Chief Medical Officer | Open-market sale | 16,035 | $85.09 | $1.4M | Form 4 |
| 2026-10-21 | Bitterman Kevin · director | Open-market sale | 13,783 | $80.23 | $1.1M | Form 4 |
| 2026-10-21 | Bitterman Kevin · director | Open-market sale | 11,470 | $80.23 | $920K | Form 4 |
| 2026-10-21 | Bitterman Kevin · director | Open-market sale | 266 | $80.23 | $21K | Form 4 |
| 2026-10-20 | Bitterman Kevin · director | Open-market sale | 2,869 | $79.95 | $229K | Form 4 |
| 2026-10-20 | Bitterman Kevin · director | Open-market sale | 2,388 | $79.95 | $191K | Form 4 |
| 2026-10-20 | Bitterman Kevin · director | Open-market sale | 55 | $79.95 | $4K | Form 4 |
| 2026-10-19 | Bitterman Kevin · director | Open-market sale | 5,937 | $79.97 | $475K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 203 reporting institutions held 41.9M shares ($2.6B, 109.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 5,586,894 | $357.2M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 2,450,221 | $156.7M |
| 3 | BlackRock, Inc. | 2,273,831 | $145.4M |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 1,735,376 | $111.0M |
| 5 | STATE STREET CORP | 1,698,244 | $108.6M |
| 6 | Atlas Venture Life Science Advisors, LLC | 1,513,875 | $96.8M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,375,430 | $87.9M |
| 8 | Frazier Life Sciences Management, L.P. | 1,354,852 | $86.6M |
| 9 | TCG Crossover Management, LLC | 1,341,862 | $85.8M |
| 10 | JPMORGAN CHASE & CO | 1,371,480 | $83.4M |
| 11 | BVF INC/IL | 1,272,312 | $81.4M |
| 12 | ORBIMED ADVISORS LLC | 1,067,550 | $68.3M |
| 13 | Siren, L.L.C. | 988,401 | $63.2M |
| 14 | Woodline Partners LP | 958,281 | $61.3M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 744,222 | $47.6M |